Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Thoracic Oncology

• Publication date

  2011-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/JTO.0b013e31822f655fPMID 22005474
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Frequency and Type of Epidermal Growth Factor Receptor Mutations in African Americans with Non-small Cell Lung Cancer

  2011cited by this paper
• Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

  2011cited by this paper
• Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation

  2010cited by this paper
• Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

  2010cited by this paper
• Association Between Age at Diagnosis and the Presence of EGFR Mutations in Female Patients with Resected Non-small Cell Lung Cancer

  2010cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.

  2009cited by this paper
• Screening for epidermal growth factor receptor mutations in lung cancer.

  2009cited by this paper
• Wood-Smoke Exposure as a Response and Survival Predictor in Erlotinib-treated Non-small Cell Lung Cancer Patients: An Open Label Phase II Study

  2008cited by this paper
• Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

  2008cited by this paper
• Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation

  2006cited by this paper
• Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

  2006cited by this paper
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

  2005cited by this paper
• ERBB receptors and cancer: the complexity of targeted inhibitors

  2005cited by this paper
• TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers.

  2005cited by this paper
• ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors

  2005cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• Differences in KRAS mutation spectrum in lung cancer cases between African Americans and Caucasians after occupational or environmental exposure to known carcinogens.

  2002cited by this paper

• EGFR variant profiles in lung adenocarcinoma from different regions of Brazil: a multi-institutional study using a rapid RT‒PCR platform

  2026cites this paper
• Molecular targets and therapies associated with poor prognosis of triple-negative breast cancer (Review)

  2025cites this paper
• Non-small cell lung cancer in Brazilian non-smokers and light-smokers: epidemiological, genotypic and clinical characteristics

  2025cites this paper
• Implementing precision oncology in Latin America to improve patient outcomes: the status quo and a call to action for key stakeholders and decision-makers

  2024cites this paper
• Lung Cancer Clinical Trials in Latin America in the Era of Cooperative Groups: A 20-Year Analysis

  2024cites this paper
• Cost-Effectiveness of Comprehensive Genomic Profiling in Patients With Non-Small Cell Lung Cancer for the Colombian Health System.

  2023cites this paper
• Diversity and Disparities in Lung Cancer Outcomes Among Minorities

  2023cites this paper
• Addressing COVID-19 Disparities Between Hispanic and Non-Hispanic White Populations of Arizona

  2023cites this paper
• Investigation of EGFR and ALK mutation frequency and treatment results in advanced non-small cell lung cancer

  2023cites this paper
• Uniting Latin America Through Research: How Regional Research Can Strengthen Local Policies, Networking, and Outcomes for Patients With Lung Cancer.

  2022cites this paper
• Clinical and pathological characteristics associated with the presence of the IS6110 Mycobacterim tuberculosis transposon in neoplastic cells from non-small cell lung cancer patients

  2022cites this paper
• Mortality Trends for Lung Cancer and Smoking Prevalence In Peru

  2022cites this paper
• LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer

  2022cites this paper
• Actionable mutations in non-small cell lung cancer in patients at hospital de Especialidades Eugenio Espejo, Ecuador 2017–2020

  2022cites this paper
• Quality of life, anxiety, depression, and distress in patients with advanced and metastatic lung cancer.

  2022cites this paper
• A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population.

  2022cites this paper
• Molecular profile of non-small cell lung cancer in reunion Island.

  2022cites this paper
• Evaluating Real World Mutational Differences Between Hispanics and Asians in NSCLC at a Large Academic Institution in Los Angeles

  2022cites this paper
• Real‐world KINDLE‐Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non‐small‐cell lung cancer

  2022cites this paper
• Challenges in Genetic Testing and Treatment Outcomes Among Hispanics With Lung Cancer.

  2022cites this paper
• Precision oncology in EGFR positive non-small cell lung cancer: breaking the 10-year barrier—a case report

  2021cites this paper
• Lung Cancer

  2021cites this paper
• Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets

  2021cites this paper
• Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells

  2021cites this paper
• Frequency of EGFR Mutations in Patients with Lung Adenocarcinoma: Comparative Study between Private and Public Healthcare Centers

  2020cites this paper
• Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.

  2020cites this paper
• Epidemiologic Features of NSCLC Gene Alterations in Hispanic Patients from Puerto Rico

  2020cites this paper
• Kirsten rat sarcoma virus protein overexpression in adenocarcinoma lung: Association with clinicopathological and histomorphological features

  2020cites this paper
• Frequency and types of EGFR mutations in Moroccan patients with non–small cell lung cancer

  2020cites this paper
• Primary Care Providers’ Knowledge, Attitudes, Beliefs, and Practice Related to Lung Cancer Screening in Five High-Risk Communities in New York City

  2020cites this paper
• Genomic characteristics and drug screening among organoids derived from non‐small cell lung cancer patients

  2020cites this paper
• Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic

  2020cites this paper
• Lung Cancer Disparities in Hispanics: Molecular Diagnosis and Use of Immunotherapy

  2020cites this paper
• Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR-tyrosine kinase inhibitor treatment in patients with non-small cell lung cancer from different ethnic groups

  2020cites this paper
• Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients

  2020cites this paper
• Comparison of the characteristics

  2020cites this paper
• Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation

  2020cites this paper
• Frequency of CYP 3 A 5 genetic polymorphisms and Tacrolimus 2 pharmacokinetics in Pediatric Liver Transplantation 3

  2019cites this paper
• Clinical and Mutational Aspects of Non-small Cell Lung Cancer in a Latin American Reference Center.

  2019cites this paper
• Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.

  2019cites this paper
• Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer

  2019cites this paper
• Precision oncology in Latin America: current situation, challenges and perspectives

  2019influential citation
• Targeted methods for molecular characterization of EGFR mutational profile in lung cancer Moroccan cohort.

  2019cites this paper
• Molecular profile of non-small cell lung cancer in northeastern Brazil

  2019cites this paper
• Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma

  2019cites this paper
• Survival and prognostic factors in non-small cell lung cancer patients with mutation of the EGFR gene treated with tyrosine kinase inhibitors in a peruvian hospital.

  2019cites this paper
• Epidermal Growth Factor Receptor Mutation Frequency in Squamous Cell Carcinoma and Its Diagnostic Performance in Cytological Samples: A Molecular and Immunohistochemical Study

  2019cites this paper
• Regional distribution of genetic mutation in lung cancer in Turkey (REDIGMA).

  2019cites this paper
• Hispanics/Latinos in the Bronx Have Improved Survival in Non-Small Cell Lung Cancer Compared with Non-Hispanic Whites

  2019cites this paper
• Use of biomarker testing in lung cancer among Puerto Rico and Florida Physicians: Results of a comparative study.

  2019cites this paper
• EGFR基因少见突变型非小细胞肺癌的临床特征及应用EGFR-TKIs治疗效果评价

  2019cites this paper
• Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients

  2018cites this paper
• Incidence of lung cancer histologic cell-types according to neighborhood factors: A population based study in California

  2018cites this paper
• Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation.

  2018cites this paper
• Targeted next generation sequencing identified a high frequency genetic mutated profile in wood smoke exposure-related lung adenocarcinoma patients

  2018cites this paper
• Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population.

  2018cites this paper
• EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP)

  2018cites this paper
• EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP).

  2018cites this paper
• Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients

  2018cites this paper
• Moving osimertinib to first-line: the right "strategy" in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?

  2018cites this paper
• Epigenomic study identifies a novel mesenchyme homeobox2-GLI1 transcription axis involved in cancer drug resistance, overall survival and therapy prognosis in lung cancer patients

  2017cites this paper
• Overall survival analysis and characterization of an EGFR mutated non small cell lung cancer (NSCLC) population

  2017cites this paper
• Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database

  2017cites this paper
• Molecular biomarkers for lung adenocarcinoma

  2017cites this paper
• Prevalence of EGFR Mutations in Lung Cancer in Uruguayan Population

  2017influential citation
• Impact of country of birth on genetic testing of metastatic lung adenocarcinomas in France: African women exhibit a mutational spectrum more similar to Asians than to Caucasians

  2017cites this paper
• A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer

  2017cites this paper
• Diagnosis of EML4-ALK Translocation With FISH, Immunohistochemistry, and Real-time Polymerase Chain Reaction in Patients With Non–Small Cell Lung Cancer

  2017cites this paper
• Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer.

  2016cites this paper
• The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

  2016cites this paper
• Gene-expression profiles in lung adenocarcinomas related to chronic wood smoke or tobacco exposure

  2016cites this paper
• Épidémiologie moléculaire du cancer bronchique

  2016cites this paper
• Variability in Cancer Risk and Outcomes Within US Latinos by National Origin and Genetic Ancestry

  2016cites this paper
• Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers.

  2016cites this paper
• Inequalities in lung cancer: a world of EGFR

  2016cites this paper
• Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin–paclitaxel

  2016cites this paper
• Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial

  2016cites this paper
• Survival of Patients with Advanced Non-Small Cell Lung Cancer Enrolled in Clinical Trials

  2016cites this paper
• [Molecular epidemiology of the lung cancer].

  2016cites this paper
• Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer

  2016cites this paper
• Translating Hispanic Genomic Factors in Lung Cancer Into Clinical Practice: EGFR Testing for Improved Outcomes

  2016influential citation
• Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia

  2016cites this paper
• The safety of afatinib for the treatment of non-small cell lung cancer

  2016cites this paper
• Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium

  2016cites this paper
• The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.

  2015cites this paper
• Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)

  2015cites this paper
• KRAS Mutation as the Biomarker of Response to Chemotherapy and EGFR-TKIs in Patients With Advanced Non–Small Cell Lung Cancer: Clues For Its Potential Use in Second-Line Therapy Decision Making

  2015cites this paper
• Lung cancer mutations and use of targeted agents in Hispanics.

  2015influential citation
• Targeted Therapies for Non-Small Cell Lung Cancer

  2015cites this paper
• Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study.

  2015cites this paper
• Medical care costs incurred by patients with smoking-related non-small cell lung cancer treated at the National Cancer Institute of Mexico

  2015cites this paper
• Molecular Spectrum of Somatic EGFR and KRAS Gene Mutations in non Small Cell Lung Carcinoma: Determination of Frequency, Distribution Pattern and Identification of Novel Variations in Indian Patients

  2015cites this paper
• Adenocarcinoma pulmonar metastásico con evolución favorable al tratamiento con ITK-EGFR en un paciente fumador.

  2015cites this paper
• Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox".

  2015cites this paper
• EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).

  2015cites this paper
• Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil

  2015cites this paper
• Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations

  2015cites this paper
• Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians

  2015cites this paper
• Twenty‐One Novel EGFR Kinase Domain variants in Patients with Nonsmall Cell Lung Cancer

  2015cites this paper
• Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.

  2014cites this paper